Company Description
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector.
The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery.
It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.
Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
| Country | British Columbia, Canada |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Dr. James A. Helliwell FRCPC, M.D. |
Contact Details
Address: 201-2067 Cadboro Bay Rd. Victoria, A1 V8R 5G4 British Columbia, Canada | |
| Phone | 250-590-3968 |
Stock Details
| Ticker Symbol | EPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| CIK Code | 0001581178 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2024 | 6-K | Report of foreign issuer |
| May 14, 2024 | 6-K | Report of foreign issuer |
| May 8, 2024 | 6-K | Report of foreign issuer |
| May 2, 2024 | 6-K | Report of foreign issuer |
| Apr 11, 2024 | 6-K | Report of foreign issuer |
| Apr 10, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Apr 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 5, 2024 | 6-K | Report of foreign issuer |